Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLOG for Localized Pancreatic Cancer
NCT05048524Phase 2Recruiting
- Sponsor
- National Health Research Institutes
- Start
- Sep 2021
- Primary completion
- Aug 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur, folinic acid, oxaliplatin, gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by National Health Research Institutes. Started Sep 2021; status: recruiting.
02
Drugs
tegafurfolinic acidoxaliplatingemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05048524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048524.